stockchase picture

Compiling comments that experts make about stocks while on public TV.

There is 1 registered member and 208 guests viewing this site

Company Index

List by Company Name

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

List by Symbol

All | 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Abbott Labs

Stock Symbol: ABT-N

Last Price Recorded: 37.7200 on 2013-05-22 01:14:01

Globe 200 day average
Google Discussions (view only)
yahoo discussion
Date Signal Expert Opinion Price
2012-05-09 WAIT Gordon Reid (Market Call Minute.) Splitting in two. Their pharma business is going to be priced more cheaply but be careful because their major drug is 47% of this. To concentrated. He would look at the other piece when they split.
 Price:
$61.230
Subject:
US EQUITIES
Bias:
BULLISH on US MARKET
Owned:
No
2008-11-21 TOP PICK Walter Gerasimowicz Diagnostic equipment stents and some new blockbuster drugs. Drug industry and healthcare services might come under some pressure with the new administration, which is the risk they may face.
 Price:
$51.520
Subject:
US & GLOBAL LARGE CAP
Bias:
UNKNOWN
Owned:
Yes
2004-05-21 TOP PICK Harvey Eisen Has paid a dividend for 80 years. Trades at a discount to the market multiple but has new drug pipeline coming on. As simple, safe story.
 Price:
$40.000
Subject:
NOT APPLICABLE
Bias:
OPTIMISTIC
Owned:
Yes
2012-10-11 TOP PICK David Burrows

2.9% dividend. Going down the path into splitting into two businesses. The pharma business has a higher than industry growth rate. Best performing sector in the market at present. The patent cliff is here and priced into the stock price.


 Price:
$69.420
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2012-11-30 TOP PICK Chyanne Fickes

Splitting as of Jan 2nd.  Trading ‘as is’ in December.  ‘New Abbot’ is their nutritional, diagnostics, vascular and diversified business, very solid sales outlooks.  Thinks there is more upside in the Drug exploration part.  Humera is one of the 5 biggest drugs globally.  5 drugs in clinical trials.  A really good pipeline. 

 Price:
$65.000
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2012-03-15 TOP PICK Gavin Graham Splitting itself into two businesses – Pharma and Infant nutrition. Couple of interesting acquisitions in the last year and a half. 3.6% yield.
Price:
$59.110
Subject:
NORTH AMERICAN - LARGE & GLOBAL EQUITIES
Bias:
DEFENSIVE
Owned:
Yes
2012-05-17 TOP PICK David Burrows This has been one of the strong companies in the ethical drug companies. Have grown their dividend 10% at year over the last 10 years. Has been a very steady company. Traded sideways for 12 years in a price range and recently in the last year, broke out. They are going to split this company into a medical products/devices company and a pure pharma business. The pharma business will have a high yield attached and the other part has opportunities for efficiencies and growth.
 Price:
$62.230
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2010-07-26 TOP PICK Christine Poole Diversified healthcare in the US. Have a branded pharmaceutical business providing drugs for arthritis, cholesterol and prostate cancer. Also had a nutritional business providing babies formula and adults’ nutrition. Also have stents, which is doing quite well globally. Trading at about 10.5X forward earnings. About 3.6% yield and have increased dividends on a regular basis.
 Price:
$49.240
Subject:
NORTH AMERICAN - LARGE
Bias:
OPTIMISTIC
Owned:
Yes
2013-02-12 TOP PICK Christine Poole

Diversified. Have nutritionals, diagnostics (nice solid business), branded generics and medical devices where they have the leading drug eluting stents. 40% of sales are coming from high-growth emerging markets. Room for margin expansion. 1.64% dividend.

 Price:
$34.300
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
Yes
2010-04-26 TOP PICK Christine Poole Pharma company. Nutritional division. Adult’s nutrition. Likes the diversification. Consistently increases dividend, about 3-1/2% at present. Recently beat numbers. Pulled earning back by 7%, but it is manageable.
Price:
$50.370
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2012-11-26 TOP PICK Brian Acker, CA

You can buy at its model price and when the company splits up it would increase value.  The balance sheet has high growth parts buried within it.  These smaller parts create more value.  The pieces are worth more than the whole.  40 increases in dividends and very shareholder friendly.  He would stay with both after the split until you can review balance sheets.

 Price:
$64.360
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2012-11-19 TOP PICK Mohsin Bashir

12 drugs under patent after a current one comes off patent.  A hepatitis drug is about to come out as well.  It could hit its 52 week high.

 Price:
$62.920
Subject:
NORTH AMERICAN - LARGE
Bias:
BULLISH
Owned:
Yes
2011-05-03 TOP PICK Barry Schwartz All different types of health care services and products. 11 times this year’s earnings. Nice valuation and entry point here.
 Price:
$52.850
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2010-01-13 TOP PICK Gordon Reid Trading at about 13X earnings. Expects revenues to grow at 8%-10% and earnings to grow 12%-14%. 2.9% dividend. 7.5% free cash flow.
 Price:
$55.290
Subject:
US EQUITIES
Bias:
BULLISH on HEALTH CARE
Owned:
Yes
2012-09-04 TOP PICK Hap (Robert) Sneddon FCSI

Has got a really good pipeline and well owned by institutions.  Great triple A balance sheet and a good yield.  Screens well against S&P stocks.  Slight sideways action.  Company will be splitting into two components in the future.  This will unlock value.

 Price:
$65.460
Subject:
TECHNICAL ANALYSIS
Bias:
CAUTIOUS
Owned:
Yes
Showing 1 to 15 of 61 entries
First Previous 1 2 3 4 5 Next Last

No Comments.

You must be logged in to comment.